INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.15 HKD | +1.56% |
|
+17.92% | -8.42% |
| Apr. 17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
| Apr. 02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,412 | 29,957 | 96,872 | 57,482 | 45,398 | 58,806 | 58,806 | - |
| Enterprise Value (EV) 1 | 20,607 | 26,589 | 89,793 | 50,957 | 39,338 | 63,018 | 53,976 | 54,501 |
| P/E ratio | -4.23 x | -16.3 x | -93.3 x | -18.2 x | -20.3 x | -48.2 x | -70 x | 330 x |
| Yield | - | - | - | - | - | - | - | 0.01% |
| Capitalization / Revenue | 2,576 x | 28.6 x | 25.2 x | 13.5 x | 9.96 x | 10.2 x | 7.78 x | 5.96 x |
| EV / Revenue | 2,174 x | 25.4 x | 23.4 x | 11.9 x | 8.63 x | 10.2 x | 7.14 x | 5.52 x |
| EV / EBITDA | -14.4 x | -16.2 x | -370 x | -16.7 x | -14.3 x | -105 x | -101 x | 113 x |
| EV / FCF | -15.5 x | -13.1 x | -113 x | -16.5 x | -14 x | -44.5 x | -57.9 x | -245 x |
| FCF Yield | -6.45% | -7.64% | -0.89% | -6.06% | -7.16% | -2.25% | -1.73% | -0.41% |
| Price to Book | 5.82 x | 5.87 x | 10.7 x | 5.54 x | 4.11 x | 5.5 x | 4.78 x | 4.97 x |
| Nbr of stocks (in thousands) | 1,153,603 | 1,262,562 | 1,402,776 | 1,462,109 | 1,534,407 | 1,622,683 | 1,622,683 | - |
| Reference price 2 | 21.16 | 23.73 | 69.06 | 39.31 | 29.59 | 36.24 | 36.24 | 36.24 |
| Announcement Date | 3/14/19 | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.477 | 1,048 | 3,844 | 4,270 | 4,556 | 6,206 | 7,561 | 9,870 |
| EBITDA 1 | -1,431 | -1,638 | -242.4 | -3,045 | -2,747 | -600.1 | -532 | 483.7 |
| EBIT 1 | -1,495 | -1,676 | -310.4 | -3,113 | -3,066 | -1,494 | -898.3 | 113.1 |
| Operating Margin | -15,779.4% | -159.96% | -8.08% | -72.9% | -67.29% | -25.03% | -11.88% | 1.15% |
| Earnings before Tax (EBT) 1 | -5,873 | -1,720 | -858.7 | -3,051 | -2,170 | -1,136 | -799.6 | 205.9 |
| Net income 1 | -5,771 | -1,720 | -998.4 | -3,138 | -2,179 | -1,197 | -827.6 | 139.9 |
| Net margin | -60,899.99% | -164.2% | -25.97% | -73.5% | -47.83% | -20.06% | -10.95% | 1.42% |
| EPS 2 | -5.000 | -1.460 | -0.7400 | -2.160 | -1.460 | -0.7526 | -0.5177 | 0.1099 |
| Free Cash Flow 1 | -1,329 | -2,030 | -796.7 | -3,090 | -2,816 | -1,222 | -931.9 | -222.3 |
| FCF margin | -14,020.87% | -193.83% | -20.73% | -72.38% | -61.8% | -20.47% | -12.32% | -2.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | 0.002500 |
| Announcement Date | 3/14/19 | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 345.5 | 702 | 984.2 | 2,860 | 1,942 | 2,328 | 2,240 | 2,317 | 2,702 | 3,505 | 3,594 | 4,158 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | -1,148 | -1,960 | -1,212 | -1,617 | -718.8 | -897.1 | -741 | -959.7 |
| Operating Margin | - | - | - | - | -59.12% | -84.17% | -54.11% | -69.8% | -26.61% | -26.24% | -20.62% | -23.08% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | -1,876 | -998.9 | -1,172 | -256.1 | -736 | - | - |
| Net income 1 | - | - | - | - | - | -1,963 | -950.5 | -1,229 | -139.1 | -885 | - | - |
| Net margin | - | - | - | - | - | -84.31% | -42.43% | -53.04% | -5.15% | -25.89% | - | - |
| EPS 2 | - | -0.8400 | -0.4600 | -0.2800 | -0.8100 | -1.350 | -0.6500 | -0.8100 | -0.0900 | -0.6000 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/29/19 | 3/30/20 | 8/26/20 | 3/29/21 | 8/25/21 | 3/29/22 | 8/25/22 | 3/28/23 | 8/23/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 3,806 | 3,368 | 7,079 | 6,525 | 6,059 | 4,424 | 4,830 | 4,305 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,329 | -2,030 | -797 | -3,090 | -2,816 | -1,222 | -932 | -222 |
| ROE (net income / shareholders' equity) | -513% | -38.4% | -14.8% | -32.8% | -20.7% | -11.1% | -6.59% | 1% |
| ROA (Net income/ Total Assets) | -135% | -25.8% | -10.5% | -22.4% | -12.9% | -6.53% | -4.19% | 0.6% |
| Assets 1 | 4,285 | 6,672 | 9,533 | 14,039 | 16,916 | 18,341 | 19,740 | 23,257 |
| Book Value Per Share 2 | 3.640 | 4.040 | 6.470 | 7.100 | 7.200 | 6.590 | 7.580 | 7.300 |
| Cash Flow per Share 2 | - | -1.410 | -0.2300 | -1.390 | -1.290 | -0.5900 | -0.4100 | 0.1100 |
| Capex 1 | 313 | 366 | 489 | 1,066 | 897 | 604 | 701 | 733 |
| Capex / Sales | 3,299.98% | 34.93% | 12.72% | 24.96% | 19.68% | 10.13% | 9.27% | 7.43% |
| Announcement Date | 3/14/19 | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
36.24
CNY
Average target price
51.18
CNY
Spread / Average Target
+41.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.42% | 8.12B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 1801 Stock
- Financials Innovent Biologics, Inc.
